Table 5.

Relative Risk of Colorectal Cancer Associated with Continuous Log-Transformed Concentrations of Plasma Adiponectin and Plasma Soluble Leptin Receptor, by Subgroups, in the Nurses’ Health Study (1990–2008) and the Health Professionals Follow-up Study (1994–2008)

	Adiponectin								Soluble Leptin Receptor
	Women				Men				Women		Men
	No. of cases	No. of controls	RR (95% CI)a	Ptrendb	No. of cases	No. of controls	RR (95% CI)a	Ptrendb	RR (95% CI)a	Ptrendb	RR (95% CI)a	Ptrendb
Body mass indexc,d
< 25	182	389	1.08 (0.69, 1.68)	0.74	102	254	0.74 (0.44, 1.24)	0.25	1.05 (0.45, 2.49)	0.91	0.57 (0.20, 1.64)	0.30
≥ 25	164	297	0.99 (0.64, 1.55)	0.97	168	265	0.77 (0.50, 1.20)	0.25	1.71 (0.59, 4.93)	0.32	0.93 (0.40, 2.15)	0.86
Pinteractione			0.60				0.69		0.89		0.38
Physical activityd,f
<15 in women, <25 in men	221	438	1.07 (0.73, 1.57)	0.72	132	257	0.62 (0.39, 0.97)	0.04	1.65 (0.75, 3.65)	0.21	0.44 (0.18, 1.10)	0.08
≥15 in women, ≥25 in men	125	248	0.82 (0.49, 1.39)	0.47	138	262	0.83 (0.51, 1.33)	0.43	0.81 (0.27, 2.43)	0.71	0.72 (0.29, 1.76)	0.47
Pinteractione			0.37				0.20		0.37		0.22
Aspirin/NSAID use
Non-regular user	187	321	1.00 (0.65, 1.54)	0.99	138	237	0.64 (0.41, 1.00)	0.05	1.41 (0.59, 3.39)	0.44	0.39 (0.16, 0.95)	0.04
Regular user	159	365	1.02 (0.66, 1.58)	0.93	132	282	0.73 (0.46, 1.16)	0.18	1.11 (0.43, 2.91)	0.82	0.84 (0.34, 2.08)	0.71
Pinteractione			0.95				0.90		0.78		0.43
Median CRP, mg/L
<1.67 in women, <1.13 in men	183	343	1.34 (0.85, 2.10)	0.20	117	259	0.94 (0.58, 1.55)	0.82	1.41 (0.59, 3.35)	0.44	0.66 (0.26, 1.67)	0.37
≥1.67 in women, ≥1.13 in men	163	343	0.74 (0.47, 1.15)	0.18	153	259	0.60 (0.38, 0.95)	0.03	0.99 (0.37, 2.66)	0.99	0.53 (0.22, 1.26)	0.15
Pinteractione			0.02				0.13		0.52		0.52
Median IL-6, pg/mL
<1.15 in women, <1.40 in men	169	342	0.90 (0.57, 1.44)	0.67	110	259	0.67 (0.40, 1.12)	0.13	1.07 (0.44, 2.60)	0.88	0.68 (0.25, 1.83)	0.44
≥1.15 in women, ≥1.40 in men	176	342	1.07 (0.70, 1.63)	0.75	160	260	0.70 (0.45, 1.07)	0.10	1.40 (0.53, 3.69)	0.50	0.58 (0.25, 1.37)	0.22
Pinteractione			0.61				0.83		0.80		0.81
Median sTNFR-2, ng/mL
<2.58 in women, <2.73 in men	152	343	1.25 (0.76, 2.05)	0.37	134	259	0.68 (0.42, 1.11)	0.12	0.97 (0.36, 2.63)	0.95	1.02 (0.40, 2.61)	0.97
≥2.58 in women, ≥2.73 in men	191	343	0.96 (0.64, 1.44)	0.84	136	260	0.72 (0.46, 1.12)	0.14	1.66 (0.70, 3.93)	0.25	0.31 (0.13, 0.75)	0.009
Pinteractione			0.44				0.99		0.82		0.17
Median C-peptide, ng/mL
<1.82 in women, <2.09 in men	153	337	1.07 (0.62, 1.83)	0.81	110	258	0.87 (0.52, 1.44)	0.59	0.86 (0.30, 2.48)	0.78	0.43 (0.15, 1.20)	0.11
≥1.82 in women, ≥2.09 in men	190	337	1.04 (0.70, 1.55)	0.85	160	258	0.59 (0.37, 0.94)	0.03	1.77 (0.74, 4.23)	0.20	0.59 (0.25, 1.39)	0.23
Pinteractione			0.78				0.15		0.20		0.87

Abbreviations: BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; IL-6, interleukin-6; MET, metabolic equivalent = (caloric need/kilogram body weight per hour activity)/(caloric need/kilogram body weight per hour at rest); NSAID, non-steroidal anti-inflammatory drug; RR, relative risk; sTNFR-2, soluble tumor necrosis factor receptor 2.

^aStratum-specific relative risks and 95% confidence intervals were estimated for the one-unit increase of log-transformed concentrations of adiponectin and soluble leptin receptor using logistic regression, with adjustment for the same covariates as in model 3 in Table 3. When stratified by regular aspirin/NSAID use, this variable was excluded from the multivariate model.

^bTest for trend was conducted using the continuous log-transformed concentrations of adiponectin and soluble leptin receptor.

^cWeight (kg)/height (m)².

^dWe further adjusted for the interacting variables in the continuous form to control for residual confounding in the stratified analysis.

^eMultiplicative interaction was evaluated between log-transformed total adiponectin and soluble leptin receptor concentrations and the stratified variables in a multivariable-adjusted logistic regression.

^fMetabolic equivalent (MET)-hours/week.